COV Stock Overview
A medical diagnostics and devices company, focuses on the development of non-invasive blood based IVD tests to detect the presence and recurrence of ovarian cancer in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Cleo Diagnostics Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.23 |
| 52 Week High | AU$0.27 |
| 52 Week Low | AU$0.14 |
| Beta | 0 |
| 1 Month Change | 24.32% |
| 3 Month Change | 27.78% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 15.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| COV | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 35.3% | -0.9% | -2.2% |
| 1Y | n/a | 14.1% | 8.8% |
Return vs Industry: Insufficient data to determine how COV performed against the Australian Medical Equipment industry.
Return vs Market: Insufficient data to determine how COV performed against the Australian Market.
Price Volatility
| COV volatility | |
|---|---|
| COV Average Weekly Movement | 18.6% |
| Medical Equipment Industry Average Movement | 10.0% |
| Market Average Movement | 8.8% |
| 10% most volatile stocks in AU Market | 17.2% |
| 10% least volatile stocks in AU Market | 3.3% |
Stable Share Price: COV's share price has been volatile over the past 3 months.
Volatility Over Time: COV's weekly volatility (19%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2021 | n/a | Richard Allman | www.cleodx.com |
Cleo Diagnostics Ltd, a medical diagnostics and devices company, focuses on the development of non-invasive blood based IVD tests to detect the presence and recurrence of ovarian cancer in Australia. It focuses on the development of triage, recurrence, and screening tests for ovarian cancer detection. The company was incorporated in 2021 and is based in Melbourne, Australia.
Cleo Diagnostics Ltd Fundamentals Summary
| COV fundamental statistics | |
|---|---|
| Market cap | AU$30.84m |
| Earnings (TTM) | AU$0 |
| Revenue (TTM) | n/a |
n/a
P/E Ration/a
P/S RatioIs COV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COV income statement (TTM) | |
|---|---|
| Revenue | AU$0 |
| Cost of Revenue | AU$0 |
| Gross Profit | AU$0 |
| Other Expenses | AU$0 |
| Earnings | AU$0 |
Last Reported Earnings
n/a
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did COV perform over the long term?
See historical performance and comparison